|Phoenix Venture Partners LLC||United States, San Mateo|
|Intellecap||United States, Palo Alto|
|Times Internet||India, Gurgaon|
|Deutsche Effecten -und Wechsel Beteiligungsgesellschaft||Germany, Jena|
|Shenzhen Nalande Investment Fund||China, Shenzhen|
|Whitefish Ventures||United States, Minnesota City|
|Alps Capital innovation||-|
|Taya Investment Company Ltd||-|
|Shikong Wuxing||China, Shanghai|
|iSeed||United Kingdom, London|
|TowerComm||United States, Raleigh|
|TUV SUD||Germany, Munich|
|MetLife Digital Accelerator powered by Techstars||United States, Cary|
|Innovative Medicines Initiative||Belgium, Berchem|
|Warren Equity Partners||United States, Jacksonville Beach|
|Manchester Tech Trust Angels||-|
|$20M||23 Apr 2019||United States, Durham|
|25 Jan 2019||United States, " United States"}|
|26 Sep 2018||United States, Fremont|
|$24M||25 Sep 2018||United States, Durham|
– Credence MedSystems, a Menlo Park, CA-based provider of drug delivery systems, raised $39.9M in funding.
– The round was led by Novartis Pharma AG and Molex Ventures LLC.
– The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the company’s platform of innovative drug delivery systems, including its connected health portfolio.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.